A Study of the Effectiveness of an Off Label Mefloquine Use for the Treatment of Patients With COVID19

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

320

Participants

Timeline

Start Date

April 8, 2020

Primary Completion Date

November 1, 2020

Study Completion Date

November 20, 2020

Conditions
Pneumonia, ViralRespiratory Failure
Interventions
DRUG

Mefloquine

"1st day: 750 mg of mefloquine per day, inside, in tablets of 250 mg 3 times a day - 1 tablet every 8 hours.~* Day 2: 500 mg of mefloquine, inside, in tablets of 250 mg 2 times a day - 1 tablet every 12 hours.~* 3rd - 7th day: 250 mg of mefloquine, inside, in tablets of 250 mg 1 time a day at the same time."

DRUG

Hydroxychloroquine

"1. st day: 800 mg of hydroxychloroquine per day, inside, in 200 mg tablets, 2 tablets 2 times a day;~2. nd - 7th day: 400 mg of hydroxychloroquine per day, inside, in tablets of 200 mg, 1 tablet 2 times a day."

COMBINATION_PRODUCT

Mefloquine + azithromycin + / - tocilizumab

"1st day: 750 mg of mefloquine per day, inside, in tablets of 250 mg 3 times a day - 1 tablet every 8 hours.~* Day 2: 500 mg of mefloquine, inside, in tablets of 250 mg 2 times a day - 1 tablet every 12 hours.~* 3rd - 7th day: 250 mg of mefloquine, inside, in tablets of 250 mg 1 time a day at the same time."

COMBINATION_PRODUCT

Hydroxychloroquine + azithromycin + / - tocilizumab

"1. st day: 800 mg of hydroxychloroquine per day, inside, in 200 mg tablets, 2 tablets 2 times a day;~2. nd - 7th day: 400 mg of hydroxychloroquine per day, inside, in tablets of 200 mg, 1 tablet 2 times a day."

Trial Locations (1)

123098

Burnasyan Federal Medical Biophysical Center FMBA of Russia, Moscow

All Listed Sponsors
lead

Burnasyan Federal Medical Biophysical Center

OTHER_GOV

NCT04347031 - A Study of the Effectiveness of an Off Label Mefloquine Use for the Treatment of Patients With COVID19 | Biotech Hunter | Biotech Hunter